Detection of Genetic Abnormalities in Cancer Cells Using Bio-Plex Immunoassays

Aberrant activation of cell-signaling networks can play significant roles in both the development and treatment of a variety of cancers. Genetic abnormalities can further deregulate these networks and confer altered responses to treatment drugs. This technical note describes the development of two sets of capture and detection antibodies specific to the L858R point mutation in EGFR and to Bcr-Abl translocations. In this study, specificity and, for Bcr-Abl, limits of detection of these aberrations in cancer cells are demonstrated, using Bio-Plex bead-based immunoassays and western blotting for comparison.